Category : IBD

Harvey-Bradshaw index for Clinical disease activity in Crohn’s Disease Parameter Input and score 1. Patient well-being(previous day) 0 = very well1 = slightly below par2 = poor3 = very poor4 = terrible 2. Abdominal pain(previous day) 0 = none 1 = mild2 = moderate3 = severe 3. Number of liquid or soft stools(previous day) blank ..

Read more

Truelove and Witts severity index for Ulcerative Colitis – Mild Moderate Severe Bowel movements (number per day) Fewer than 4 4–6 6 or more plus at least 1 of the features of systemic upset (marked with * below) Blood in stools No more than small amounts of blood Between mild and severe Visible blood Fever ..

Read more

Infliximab Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Infliximab for Induction and Maintenance Therapy ..

Read more

Vedolizumab vs Adalimumab Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative ..

Read more

Vedolizumab Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Vedolizumab as Induction and Maintenance Therapy ..

Read more

Prediction of complications in Crohn’s disease Risk factors:-Age below 40 y-Disease location-perianal at diagnosis-requirement of steroid treatment in first flare References: Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650-656. doi:10.1053/j.gastro.2..

Read more

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane 2015 Related articles (Crohn):*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) ..

Read more

Mild to moderate Ulcerative Colitis: 5-ASA efficacy and dosage A Cochrane review: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis 5-ASA vs placebo for induction of remission in Ulcerative Colitis High dose 5-ASA vs low dose 5-ASA for induction in Ulcerative Colitis Author’s conclusions: 5-ASA was superior to placebo and no more effective ..

Read more

Several diagnostic and treatment algorithms for pouchitis Pouchitis disease activity index: Pouchitis diagnostic algorithm Shen 2013 Clin Gastroenterol Hepatol. Pouchitis treatment algorithm. Shen 2013 Clin Gastroenterol Hepatol. Alternative treatment algorithm (reference?) Segal et al. Systematic Review With Meta-Analysis: The Management of Chronic Refractory Pouchitis With an Evidence-Based Treatment Algorithm. Aliment Pharmacol Ther Actions 2017 Nguyen ..

Read more

Cumulative risk of main outcomes on Left sided Ulcerative Colitis phenotype, disease activity and Colorectal Cancer. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Results taken from the abstract of the article Left-sided colitis is the most frequent location, and disease extension is observed in 10%–30% of patients. Majority of patients ..

Read more

Mild-to-moderate Ulcerative Colitis induction therapy: budesonide (CORE studies) Once-daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study William J Sandborn, Simon Travis, Luigi Moro , Richard Jones, Theres Gautille, Robert Bagin , Michael Huang, Phil Yeung, E David Ballard Background & aims: Budesonide is a corticosteroid with minimal systemic corticosteroid activity ..

Read more

Methotrexate compared to placebo for induction of remission in refractory Crohn’s disease. Related articles (Crohn):*Azathioprine Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) For ..

Read more

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial Cyriel Y Ponsioen, E Joline de Groof , Emma J Eshuis , Tjibbe J Gardenbroek , Patrick M M Bossuyt, Ailsa Hart, Janindra Warusavitarne, Christianne J Buskens, Ad A van Bodegraven, Menno A Brink, Esther C J Consten, Bart A van Wagensveld, Marno C M Rijk, Rogier M P H Crolla, Casper G Noomen, Alexander P ..

Read more

Thiopurine metabolite metabolism, screening, monitoring and side effect management. References: Lauren Beswick, Antony B Friedman & Miles P Sparrow (2014) The role ofthiopurine metabolite monitoring in inflammatory bowel disease, Expert Review of Gastroenterology & Hepatology, 8:4, 383-392, DOI: 10.1586/17474124.2014.894878 Warner B, Johnston E, Arenas-Hernandez M, et al. Frontline Gastroenterology Published Online First. doi:10.1136/flgastro-2..

Read more

Infliximab with Azathiopurine in Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Infliximab Azathiopurine combination therapy in ..

Read more

Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Adalimumab for induction of clinical remission in moderately to severely active ulcerative ..

Read more

Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Meta-analysis MTX (methotrexate) vs placebo in maintenance ulcerative colitis. The ..

Read more

Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) ..

Read more